menu search

Eli lilly stock hits new high on positive crohn's disease study results

Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage study to test...

October 12, 2023, 8:35 am

Regeneron gets fda green light on first treatment for life-threatening immune disease

Regeneron Pharmaceuticals Inc. REGN, +0.55% said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a ra...

August 18, 2023, 2:11 pm

Avanos (avns) q2 earnings and revenues fall shy of estimates

Despite strength in Avanos' (AVNS) digestive Health segment, its overall second-quarter results reflect...

August 10, 2023, 1:00 pm

Us digestive health announces four new providers to its gastroenterology practice

The providers will support the practice’s expansion in Bucks County, Pennsylvania EXTON, Pa., June 13, 2023 (GLOBE NEWSWIRE) — US ...

June 13, 2023, 3:00 pm

Otc vitamins & dietary supplements market to surpass us$ 100 billion by 2032; capsules to be most sought after component: fact.mr report

OTC Vitamins and Dietary Supplements Market By Form (Liquid, Powder, Tablet, Capsule) By Function (Immune Health, ...

May 18, 2023, 2:00 pm

Phathom pharmaceuticals presents new data at digestive disease week® (ddw) 2023

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demog...

May 9, 2023, 12:00 pm

Immunic presents data showing beneficial effects of imu-856 on gut health at digestive disease week 2023

Immunic Inc (NASDAQ:IMUX) said it has presented new clinical and pre-clinical data on the molecule IMU-856 at ...

May 8, 2023, 8:17 am

Cult food highlights details on bflora, its proprietary probiotic blend for dogs and cats

CULT Food Science Corp (CSE:CULT, OTCQB:CULTF) has said that its proprietary probiotic blend designed for the gastrointestinal systems of dogs and ca...

May 2, 2023, 8:46 am

Global corn fiber market is estimated to cross us$ 3.16 billion by 2033 amid increasing benefits of soluble corn fiber in digestive health | future market insights, inc.

According to the FMI analysis, the market for corn fiber in Europe is anticipated to expand at a CAGR of 10% from 2023 to 2033. The growth can be attr...

May 2, 2023, 12:30 am

Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting

PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis Patients PCS12852 Improved Both Gastroparesis Symptom Sco...

April 28, 2023, 12:15 pm

Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting

HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...

April 28, 2023, 8:15 am

Cvs health (cvs) team up to treat digestive disorder virtually

CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual ...

April 10, 2023, 12:09 pm

Neuraxis seeks $15 million ipo for device expansion

Neuraxis, Inc. has filed proposed terms for a $15 million U.S. IPO. The firm is developing neuromodulation technologies for the treatment of various p...

January 27, 2023, 3:08 pm

Capital digestive care announces three key executive leadership changes

Silver Spring, MD, Jan. 10, 2023 (GLOBE NEWSWIRE) — Capital digestive Care has announced three change...

January 10, 2023, 3:18 pm

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am


Search within

Pages Search Results: